Imunon announces abstract on Phase 1 proof-of-concept trial of IMNN-101

IMUNON (IMNN) announced that an abstract highlighting Phase 1 proof-of-concept clinical trial results of IMNN-101, an investigational DNA plasmid vaccine based on the Company’s proprietary PlaCCine technology platform, was accepted for oral presentation at the 10th International Conference on Vaccines Research & Development. The meeting is being held November 5-7, 2025, in Boston, MA. In the Phase 1 trial, designed to demonstrate the potential of IMUNON’s technology as a viable alternative to current vaccines including approved messenger RNA vaccines, IMNN-101 was administered as a single dose vaccine without a booster dose in study participants who were previously vaccinated against the Omicron XBB1.5 variant. Study participants had high baseline immune characteristics, presumably from prior infection and/or multiple previous vaccinations against COVID-19, and ongoing infection. Modest increases in T-cell responses were seen in trial participants who received multiple immunizations before the study.